- Jin-Lin Hou, MD
- Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and accounts for about 6% of all new cancer cases diagnosed worldwide (nearly 750,000 new cases/year), with nearly half of these cases reported in China alone. Because liver is a silent organ, most of HCC is discovered as middle and late stages, which makes HCC have a low cure rate and high mortality. For this reason, accurate diagnosis in the early stage is crucial for HCC. This is a huge part of unmet medical needs. The effectiveness of early detection in HCC is dependent on not only the development of science and technology but also the advance of public health and the cancer awareness of people in a local region. Nowadays, it is gratifying that WHO and government of many countries have paid more and more attention to the advance of public health and taken many powerful measures for cancer early-detection programs. Meanwhile, science and technology revolving around HCC early diagnosis are making great progress day by day, including surveillance for HCC in high-risk population, the diagnostic strategy of indeterminate hepatic nodule, advances in new diagnostic biomarkers, etc. In this regard, this special issue is developed for the close attention and promotion of research advances and academic communication in this field.
Submission Deadline31 Dec 2018